Temecula, CA (PRWEB) October 27, 2006
CVAC Systems, Inc. (http://www.cvacsystems.com) announced today that it has formed a scientific advisory board to investigate the strengths and limitations of the cyclic variations in altitude conditioning (CVAC) process in the management and treatment of diabetes, insulin resistance and metabolic syndrome.
Anne L. Friedlander, Ph.D., Mike Nichols, M.D., Michael W. Schwartz, M.D., and Jeffrey D. White, Ph.D., each possessing diverse backgrounds and expertise, represent a multi-faceted approach for the investigation of this complex, deadly epidemic.
Anne L. Friedlander, Ph.D., has broad research experience in the field of exercise physiology, with a special emphasis on the regulation of substrate use during exercise and environmental physiology (high altitude and heat). Dr. Friedlander's strong understanding of high-altitude physiology and metabolism is well suited to identify mechanisms underlying metabolic effects of the CVAC process.
Dr. Friedlander is currently the Director of the Exercise Physiology Lab within the Clinical Studies Unit at the Veterans Affairs Palo Alto Health Care System, and a consulting professor of Human Biology at Stanford University.
Mike Nichols, M.D.'s background in scientific theory construction at the University of Chicago, where he obtained his first graduate degree in the Philosophy of Science, led him to question current medical approaches to complex medical problems. After obtaining his medical degree from Loyola University of Chicago, and completing his residency through Stanford University, Dr. Nichols practiced medicine in the Bay area, and eventually founded the TempusClinic. TempusClinic has developed a four-part integrated program designed to help its clients achieve metabolic turnaround by using a combination of the best of today's science, the most advanced technologies, and the most natural means so its clients can achieve their health and fitness goals.
Michael W. Schwartz, M.D., an Endocrinologist, is currently Professor and Head of the Section of Clinical Nutrition in the Division of Metabolism, Endocrinology and Nutrition at the University of Washington. Concurrently, he is Founding Director of the Weight Disorders Clinic at Harborview Medical Center, Seattle, WA. Dr. Schwartz has been continuously funded by the NIH to study neuroendocrine control of food intake, body weight and glucose metabolism for more than 16 years. During this time, he published more than 150 papers on these and related topics, has won numerous awards for his research. Dr. Schwartz serves on scientific review and advisory panels for several organizations including the NIH, and the Diabetes Center at UCSF, among others, and serves on the Editorial Boards of The Journal of Clinical Investigation, Diabetes, Endocrinology, The American Journal of Physiology, Endocrine Reviews and Frontiers in Neuroendocrinology.
Jeffery D. White, PhD. has been an entrepreneur for more than 12 years specializing in biopharmaceuticals and clinical informatics, gaining extensive experience in developing business models, financial projections, and defining corporate strategy. During this time, Dr. White has held positions including Senior Science Consultant at Bogart, Delafield, Ferrier LLC, a strategic consulting company for the pharmaceutical industry, and Chief Scientific Officer of Predict, Inc., a clinical bioinformatics company. Dr. White founded and was President of Metacrine Sciences, Inc., a virtual drug discovery company, and was a founding scientist and Director of Biochemistry and Cell Biology at Trophix Pharmaceuticals, Inc. Prior to moving into industry, Dr. White was a tenured Associate Professor of Medicine/Endocrinology and Neurobiology & Behavior at SUNY Stony Brook. He graduated cum laude from Wesleyan University and received his Ph.D. from SUNY Stony Brook. Dr. White currently maintains an appointment as Adjunct Associate Professor in the Department of Animal Sciences, Rutgers University.
About CVAC Systems
CVAC Systems, Inc.'s proprietary patent-pending process, cyclic variations in altitude conditioning, encompasses scientifically validated intermittent hypoxic (high altitude) training (IHT) to trigger the human body's natural high-altitude adaptation response. The high-altitude adaptation response is understood to evoke increases in red blood cell count, capillary density and metabolic improvement.
The company is seeking to place CVAC instruments (pressure vessels) at key luminary research sites for the development of several patent-pending applications such as performance enhancement, disease prevention, therapy and advanced health. Moreover, CVAC Systems is focusing its efforts to study the potential value of the CVAC process in managing and treating diabetes, insulin resistance, and metabolic syndrome.
Please note: The information contained within this document is intended for prospective researchers only, and is not intended for patients or health care providers. Any references to therapeutic applications are for discussion and research purposes only.
Copyright © 2006, CVAC Systems, Inc. All rights reserved. Cyclic Variations in Altitude Conditioning, CVAC and CVAC logo are trademarks or registered trademarks of CVAC Systems, Inc. in the United States and/or other Countries. All other trademarks belong to their respective owners. No affiliation is expressed or implied herein.
# # #